experiment,contrast,cell_line,morphology,tissue,disease,drug,target,dose,time_hr
hh1,dac_96hr,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Decitabine,Human Deoxyribonucleic acid (hDNA),NA,96
hh1,dac_hh1_10um_96hr,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Decitabine + HH1,Human Deoxyribonucleic acid (hDNA); Cyclin-dependent kinase 9 (CDK9),10uM,96
hh1,dac_hh1_25um_96hr,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Decitabine + HH1,Human Deoxyribonucleic acid (hDNA); Cyclin-dependent kinase 9 (CDK9),25uM,96
hh1,hh1_24hr,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",HH1,Cyclin-dependent kinase 9 (CDK9),10uM,24
hh1,hh1_25um_96hr,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",HH1,Cyclin-dependent kinase 9 (CDK9),25uM,96
hh1,hh1_2hr,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",HH1,Cyclin-dependent kinase 9 (CDK9),10uM,2
hh1,hh1_4hr,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",HH1,Cyclin-dependent kinase 9 (CDK9),10uM,4
hh1,hh1_8hr,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",HH1,Cyclin-dependent kinase 9 (CDK9),10uM,8
hh1,hh1_96hr,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",HH1,Cyclin-dependent kinase 9 (CDK9),10uM,96
hh1,tetOff,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",tetOff,,NA,72
pladb,pladb_10nM,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Pladienolide B,mRNA splicing inhibitor,10nM,72
pladb,pladb_150nM,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Pladienolide B,mRNA splicing inhibitor,150nM,72
PRJNA254756,pIND_shMiz1.minusDox_BI8622,LS174T,epithelial,large intestine; colon,Carcinoma,pIND_shMiz1.minusDox_BI8622,Ubiquitin ligase HUWE1 inhibitor,10uM,NA
PRJNA254756,pIND_shMiz1.plusDox_BI8622,LS174T,epithelial,large intestine; colon,Carcinoma,pIND_shMiz1.plusDox_BI8622,Ubiquitin ligase HUWE1 inhibitor,10uM,NA
PRJNA254756,pLKO_empty.BI8622,LS174T,epithelial,large intestine; colon,Carcinoma,pLKO_empty.BI8622,Ubiquitin ligase HUWE1 inhibitor,10uM,NA
PRJNA254756,shHUWE1.BI8622,LS174T,epithelial,large intestine; colon,Carcinoma,shHUWE1.BI8622,Ubiquitin ligase HUWE1 inhibitor,10uM,NA
PRJNA260377,cmml1_responder,BM MNC,hematopoietic,bone marrow,chronic myelomonocytic leukemia,Decitabine,methylcytosine,20 mg/m2/day i.v.,3 cycles 5d/28d
PRJNA260377,cmml2_responder,BM MNC,hematopoietic,bone marrow,chronic myelomonocytic leukemia,Decitabine,methylcytosine,20 mg/m2/day i.v.,3 cycles 5d/28d
PRJNA260377,responder,BM MNC,hematopoietic,bone marrow,chronic myelomonocytic leukemia,Decitabine,methylcytosine,20 mg/m2/day i.v.,3 cycles 5d/28d
PRJNA265187,dac,SW48,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Decitabine,methylcytosine,NA,NA
PRJNA265187,dac_siCHD4,SW48,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Decitabine + siCHD4,methylcytosine + Chromodomain Helicase DNA Binding Protein 4,NA,NA
PRJNA265187,siCHD4,SW48,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",siCHD4,siCHD4,NA,NA
PRJNA265187,siDMNT1,SW48,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",siDMNT1,siDMNT1,NA,NA
PRJNA265187,siDNMT1_siCHD4,SW48,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",siDNMT1 + siCHD4,siDNMT1 + siCHD4,NA,NA
PRJNA315294,doxorubicin.300nM.16h,CRC,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Doxorubicin,DNA topoisomerase II (TOP2); TERT messenger RNA (TERT mRNA),300nM,16
PRJNA315294,hct_dox,HCT116,epithelial,large intestine; colon,Carcinoma,Doxorubicin,DNA topoisomerase II (TOP2); TERT messenger RNA (TERT mRNA),300nM,16
PRJNA315294,hct_ko_dox,HCT116_p53_KO,epithelial,large intestine; colon,Carcinoma,Doxorubicin,DNA topoisomerase II (TOP2); TERT messenger RNA (TERT mRNA),300nM,16
PRJNA315294,hct_wt_dox,HCT116_p53_WT,epithelial,large intestine; colon,Carcinoma,Doxorubicin,DNA topoisomerase II (TOP2); TERT messenger RNA (TERT mRNA),300nM,16
PRJNA315294,rko_dox,RKO,epithelial,large intestine; colon,Carcinoma,Doxorubicin,DNA topoisomerase II (TOP2); TERT messenger RNA (TERT mRNA),300nM,16
PRJNA315294,rko_ko_dox,RKO_p53_KO,epithelial,large intestine; colon,Carcinoma,Doxorubicin,DNA topoisomerase II (TOP2); TERT messenger RNA (TERT mRNA),300nM,16
PRJNA315294,rko_wt_dox,RKO_p53_WT,epithelial,large intestine; colon,Carcinoma,Doxorubicin,DNA topoisomerase II (TOP2); TERT messenger RNA (TERT mRNA),300nM,16
PRJNA315294,sw48_dox,SW48,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Doxorubicin,DNA topoisomerase II (TOP2); TERT messenger RNA (TERT mRNA),300nM,16
PRJNA315294,sw48_ko_dox,SW48_p53_KO,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Doxorubicin,DNA topoisomerase II (TOP2); TERT messenger RNA (TERT mRNA),300nM,16
PRJNA315294,sw48_wt_dox,SW48_p53_WT,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Doxorubicin,DNA topoisomerase II (TOP2); TERT messenger RNA (TERT mRNA),300nM,16
PRJNA315414,MOLT4.dBET6.2,MOLT-4,lymphoblast,T-lymphocyte,Acute lymphoblastic leukemia,dBET6,Bromodomain and extraterminal domain protein (BET),,2
PRJNA315414,MOLT4.dBET6.6,MOLT-4,lymphoblast,T-lymphocyte,Acute lymphoblastic leukemia,dBET6,Bromodomain and extraterminal domain protein (BET),,6
PRJNA315414,primary_T_cell.dBET6.0,T-ALL,primary human cells,T-lymphocyte,Acute lymphoblastic leukemia,dBET6,Bromodomain and extraterminal domain protein (BET),,
PRJNA315414,T_ALL_PDX.dBET6.0,T-ALL_PDX,primary human cells,T-lymphocyte,Acute lymphoblastic leukemia,dBET6,Bromodomain and extraterminal domain protein (BET),,
PRJNA315414,MOLT4.JQ1.2,MOLT-4,lymphoblast,T-lymphocyte,Acute lymphoblastic leukemia,JQ1,Bromodomain-containing protein 2 (BRD2),,2
PRJNA315414,MOLT4.JQ1.6,MOLT-4,lymphoblast,T-lymphocyte,Acute lymphoblastic leukemia,JQ1,Bromodomain-containing protein 2 (BRD2),,6
PRJNA315414,primary_T_cell.JQ1.0,T-ALL,primary human cells,T-lymphocyte,Acute lymphoblastic leukemia,JQ1,Bromodomain-containing protein 2 (BRD2),,
PRJNA315414,T_ALL_PDX.JQ1.0,T-ALL_PDX,primary human cells,T-lymphocyte,Acute lymphoblastic leukemia,JQ1,Bromodomain-containing protein 2 (BRD2),,
PRJNA316529,deazaneplanocinA,HL-60,promyeloblast,myeloid,acute promyelocytic leukemia,3-deazaneplanocin A,Adenosylhomocysteinase (AHCY),1000nM,72
PRJNA316529,dac,HL-60,promyeloblast,myeloid,acute promyelocytic leukemia,Decitabine,Human Deoxyribonucleic acid (hDNA),100nM,72
PRJNA316529,dac_deazaneplanocinA,HL-60,promyeloblast,myeloid,acute promyelocytic leukemia,Decitabine + 3-deazaneplanocin A,Human Deoxyribonucleic acid (hDNA); Adenosylhomocysteinase (AHCY),100nM + 1000nM,72
PRJNA318019,dac,GBM,epithelial,brain,Glioblastoma,Decitabine,Human Deoxyribonucleic acid (hDNA),1uM,72
PRJNA318019,lnt_dac,LNT-299,epithelial,brain,Glioblastoma,Decitabine,Human Deoxyribonucleic acid (hDNA),1uM,72
PRJNA318019,t98g_dac,T98G,epithelial,brain,Glioblastoma,Decitabine,Human Deoxyribonucleic acid (hDNA),1uM,72
PRJNA318019,u87_dac,U-87,epithelial,brain,Glioblastoma,Decitabine,Human Deoxyribonucleic acid (hDNA),1uM,72
PRJNA335388,bc_dox,MDA-MB231,epithelial,breast,Adenocarcinoma,Doxorubicin,DNA topoisomerase II (TOP2); TERT messenger RNA (TERT mRNA),1uM,72
PRJNA335388,doxorubicin.1uM,Breast/Osteosarcoma,epithelial,breast + bone,,Doxorubicin,DNA topoisomerase II (TOP2); TERT messenger RNA (TERT mRNA),1uM,72
PRJNA335388,os_dox,U2OS,epithelial,bone,Osteosarcoma,Doxorubicin,DNA topoisomerase II (TOP2); TERT messenger RNA (TERT mRNA),1uM,72
PRJNA335388,bc_eto,MDA-MB231,epithelial,breast,Adenocarcinoma,Etoposide,DNA topoisomerase II (TOP2),20uM,72
PRJNA335388,etoposide.20uM,Breast/Osteosarcoma,epithelial,breast + bone,,Etoposide,DNA topoisomerase II (TOP2),20uM,72
PRJNA335388,os_eto,U2OS,epithelial,bone,Osteosarcoma,Etoposide,DNA topoisomerase II (TOP2),20uM,72
PRJNA335388,bc_mms,MDA-MB231,epithelial,breast,Adenocarcinoma,MMS,Human Deoxyribonucleic acid (hDNA),40 ug/mL,72
PRJNA335388,mms.40ug_ml,Breast/Osteosarcoma,epithelial,breast + bone,,MMS,Human Deoxyribonucleic acid (hDNA),40 ug/mL,72
PRJNA335388,os_mms,U2OS,epithelial,bone,Osteosarcoma,MMS,Human Deoxyribonucleic acid (hDNA),40 ug/mL,72
PRJNA335388,bc_pac,MDA-MB231,epithelial,breast,Adenocarcinoma,Paclitaxel,Apoptosis regulator Bcl-2 (BCL-2); Tubulin beta (TUBB),0.2uM,72
PRJNA335388,os_pac,U2OS,epithelial,bone,Osteosarcoma,Paclitaxel,Apoptosis regulator Bcl-2 (BCL-2); Tubulin beta (TUBB),0.2uM,72
PRJNA335388,paclitaxel.02uM,Breast/Osteosarcoma,epithelial,breast + bone,,Paclitaxel,Apoptosis regulator Bcl-2 (BCL-2); Tubulin beta (TUBB),0.2uM,72
PRJNA340369,TF_1.Cyclocreatine,TF-1,lymphoblast,myeloid,Erythroleukemia,Cyclocreatine,Protein kinase (PK),3mM,24
PRJNA340369,UCSD_AML1.Cyclocreatine,UCSD-AML1,lymphoblast,myeloid,Acute myeloid leukemia,Cyclocreatine,Protein kinase (PK),3mM,24
PRJNA340369,UT_7.Cyclocreatine,UT-7,lymphoblast,myeloid,Acute myeloid leukemia,Cyclocreatine,Protein kinase (PK),3mM,24
PRJNA352461,Azacitidine,BM MNC,patient-derived AML,bone marrow,Acute myeloid leukemia,Azacitidine,DNA [cytosine-5]-methyltransferase (DNMT),NA,NA
PRJNA352461,LSD1i,BM MNC,patient-derived AML,bone marrow,Acute myeloid leukemia,LSD1i,Lysine-specific demethylase 1 (LSD1/KDM1A),NA,NA
PRJNA352461,LSD1i_Azacitidine,BM MNC,patient-derived AML,bone marrow,Acute myeloid leukemia,LSD1i_Azacitidine,Lysine-specific demethylase 1 (LSD1/KDM1A); DNA [cytosine-5]-methyltransferase (DNMT),NA,NA
PRJNA379584,Afatinib.6.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Afatinib,,ED20 and 1/10 of it,6
PRJNA379584,Afatinib.24.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Afatinib,,ED20 and 1/10 of it,24
PRJNA379584,Alisertib.6.2,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Alisertib,,ED20 and 1/10 of it,6
PRJNA379584,Alisertib.24.3,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Alisertib,,ED20 and 1/10 of it,24
PRJNA379584,Arachidonyl.6.11A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Arachidonyl,,ED20 and 1/10 of it,6
PRJNA379584,Arachidonyl.24.11A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Arachidonyl,,ED20 and 1/10 of it,24
PRJNA379584,At13387.6.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,At13387,,ED20 and 1/10 of it,6
PRJNA379584,At13387.24.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,At13387,,ED20 and 1/10 of it,24
PRJNA379584,AUY922.6.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,AUY922,,ED20 and 1/10 of it,6
PRJNA379584,AUY922.24.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,AUY922,,ED20 and 1/10 of it,24
PRJNA379584,AZD6482.6.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,AZD6482,,ED20 and 1/10 of it,6
PRJNA379584,AZD6482.24.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,AZD6482,,ED20 and 1/10 of it,24
PRJNA379584,AZD7762.6.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,AZD7762,,ED20 and 1/10 of it,6
PRJNA379584,AZD7762.24.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,AZD7762,,ED20 and 1/10 of it,24
PRJNA379584,AZD8055.6.1,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,AZD8055,,ED20 and 1/10 of it,6
PRJNA379584,AZD8055.24.1,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,AZD8055,,ED20 and 1/10 of it,24
PRJNA379584,Bafetinib.6.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Bafetinib,,ED20 and 1/10 of it,6
PRJNA379584,Bafetinib.24.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Bafetinib,,ED20 and 1/10 of it,24
PRJNA379584,Bardoxolone_methyl.6.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Bardoxolone_methyl,,ED20 and 1/10 of it,6
PRJNA379584,Bardoxolone_methyl.24.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Bardoxolone_methyl,,ED20 and 1/10 of it,24
PRJNA379584,Belinostat.6.1,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Belinostat,,ED20 and 1/10 of it,6
PRJNA379584,Belinostat.24.1,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Belinostat,,ED20 and 1/10 of it,24
PRJNA379584,Bexarotene.6.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Bexarotene,,ED20 and 1/10 of it,6
PRJNA379584,Bexarotene.24.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Bexarotene,,ED20 and 1/10 of it,24
PRJNA379584,BGJ398.6.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,BGJ398,,ED20 and 1/10 of it,6
PRJNA379584,BGJ398.24.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,BGJ398,,ED20 and 1/10 of it,24
PRJNA379584,BI_2536.6.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,BI_2536,,ED20 and 1/10 of it,6
PRJNA379584,BI_2536.24.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,BI_2536,,ED20 and 1/10 of it,24
PRJNA379584,BIO.6.11B,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,BIO,,ED20 and 1/10 of it,6
PRJNA379584,BIO.6.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,BIO,,ED20 and 1/10 of it,6
PRJNA379584,BIO.24.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,BIO,,ED20 and 1/10 of it,24
PRJNA379584,BKM120.6.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,BKM120,,ED20 and 1/10 of it,6
PRJNA379584,BKM120.24.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,BKM120,,ED20 and 1/10 of it,24
PRJNA379584,BMS_754807.6.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,BMS_754807,,ED20 and 1/10 of it,6
PRJNA379584,BMS_754807.24.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,BMS_754807,,ED20 and 1/10 of it,24
PRJNA379584,Bortezomib.6.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Bortezomib,,ED20 and 1/10 of it,6
PRJNA379584,Bortezomib.6.10A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Bortezomib,,ED20 and 1/10 of it,6
PRJNA379584,Bortezomib.24.10A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Bortezomib,,ED20 and 1/10 of it,24
PRJNA379584,Bortezomib.6.10B,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Bortezomib,,ED20 and 1/10 of it,6
PRJNA379584,Bortezomib.24.10B,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Bortezomib,,ED20 and 1/10 of it,24
PRJNA379584,Brefeldin_A.6.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Brefeldin_A,,ED20 and 1/10 of it,6
PRJNA379584,Brefeldin_A.24.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Brefeldin_A,,ED20 and 1/10 of it,24
PRJNA379584,Brivanib.6.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Brivanib,,ED20 and 1/10 of it,6
PRJNA379584,Brivanib.24.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Brivanib,,ED20 and 1/10 of it,24
PRJNA379584,BYL719.6.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,BYL719,,ED20 and 1/10 of it,6
PRJNA379584,BYL719.24.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,BYL719,,ED20 and 1/10 of it,24
PRJNA379584,CAY10618_in_Methanol.6.12B,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,CAY10618_in_Methanol,,ED20 and 1/10 of it,6
PRJNA379584,CAY10618_in_Methanol.24.12B,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,CAY10618_in_Methanol,,ED20 and 1/10 of it,24
PRJNA379584,CD_437.6.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,CD_437,,ED20 and 1/10 of it,6
PRJNA379584,CD_437.24.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,CD_437,,ED20 and 1/10 of it,24
PRJNA379584,Cerulenin.6.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Cerulenin,,ED20 and 1/10 of it,6
PRJNA379584,Cerulenin.24.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Cerulenin,,ED20 and 1/10 of it,24
PRJNA379584,CHM_1.6.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,CHM_1,,ED20 and 1/10 of it,6
PRJNA379584,CHM_1.24.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,CHM_1,,ED20 and 1/10 of it,24
PRJNA379584,Ciclopirox.6.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Ciclopirox,,ED20 and 1/10 of it,6
PRJNA379584,Ciclopirox.24.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Ciclopirox,,ED20 and 1/10 of it,24
PRJNA379584,Ciclopirox.24.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Ciclopirox,,ED20 and 1/10 of it,24
PRJNA379584,Crizotinib.6.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Crizotinib,,ED20 and 1/10 of it,6
PRJNA379584,Crizotinib.24.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Crizotinib,,ED20 and 1/10 of it,24
PRJNA379584,Dasatinib.6.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Dasatinib,,ED20 and 1/10 of it,6
PRJNA379584,Dasatinib.24.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Dasatinib,,ED20 and 1/10 of it,24
PRJNA379584,DBeQ.6.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,DBeQ,,ED20 and 1/10 of it,6
PRJNA379584,DBeQ.24.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,DBeQ,,ED20 and 1/10 of it,24
PRJNA379584,Dinaciclib.6.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Dinaciclib,,ED20 and 1/10 of it,6
PRJNA379584,Dinaciclib.24.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Dinaciclib,,ED20 and 1/10 of it,24
PRJNA379584,Docetaxel.6.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Docetaxel,,ED20 and 1/10 of it,6
PRJNA379584,Docetaxel.24.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Docetaxel,,ED20 and 1/10 of it,24
PRJNA379584,Doxorubicin.6.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Doxorubicin,,ED20 and 1/10 of it,6
PRJNA379584,Doxorubicin.24.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Doxorubicin,,ED20 and 1/10 of it,24
PRJNA379584,Entinostat.6.1,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Entinostat,,ED20 and 1/10 of it,6
PRJNA379584,Entinostat.24.1,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Entinostat,,ED20 and 1/10 of it,24
PRJNA379584,Epigallocatechin_gallate.6.11A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Epigallocatechin_gallate,,ED20 and 1/10 of it,6
PRJNA379584,Epigallocatechin_gallate.24.11A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Epigallocatechin_gallate,,ED20 and 1/10 of it,24
PRJNA379584,Erastin.6.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Erastin,,ED20 and 1/10 of it,6
PRJNA379584,Erastin.24.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Erastin,,ED20 and 1/10 of it,24
PRJNA379584,Erastin.6.10A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Erastin,,ED20 and 1/10 of it,6
PRJNA379584,Erastin.24.10A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Erastin,,ED20 and 1/10 of it,24
PRJNA379584,Fingolimod.6.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Fingolimod,,ED20 and 1/10 of it,6
PRJNA379584,Fingolimod.24.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Fingolimod,,ED20 and 1/10 of it,24
PRJNA379584,FK866.6.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,FK866,,ED20 and 1/10 of it,6
PRJNA379584,FK866.24.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,FK866,,ED20 and 1/10 of it,24
PRJNA379584,Flavopiridol.6.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Flavopiridol,,ED20 and 1/10 of it,6
PRJNA379584,Flavopiridol.24.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Flavopiridol,,ED20 and 1/10 of it,24
PRJNA379584,Fluvastatin.6.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Fluvastatin,,ED20 and 1/10 of it,6
PRJNA379584,Fluvastatin.24.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Fluvastatin,,ED20 and 1/10 of it,24
PRJNA379584,Foretinib.6.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Foretinib,,ED20 and 1/10 of it,6
PRJNA379584,Foretinib.24.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Foretinib,,ED20 and 1/10 of it,24
PRJNA379584,GDC_0941.6.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,GDC_0941,,ED20 and 1/10 of it,6
PRJNA379584,GDC_0941.24.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,GDC_0941,,ED20 and 1/10 of it,24
PRJNA379584,Gemcitabine.6.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Gemcitabine,,ED20 and 1/10 of it,6
PRJNA379584,Gemcitabine.24.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Gemcitabine,,ED20 and 1/10 of it,24
PRJNA379584,Gemcitabine.6.10A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Gemcitabine,,ED20 and 1/10 of it,6
PRJNA379584,Gemcitabine.24.10A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Gemcitabine,,ED20 and 1/10 of it,24
PRJNA379584,Gossypol.6.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Gossypol,,ED20 and 1/10 of it,6
PRJNA379584,Gossypol.24.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Gossypol,,ED20 and 1/10 of it,24
PRJNA379584,GSK1210151A.6.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,GSK1210151A,,ED20 and 1/10 of it,6
PRJNA379584,GSK1210151A.24.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,GSK1210151A,,ED20 and 1/10 of it,24
PRJNA379584,GSK1210151A.6.10A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,GSK1210151A,,ED20 and 1/10 of it,6
PRJNA379584,GSK1210151A.24.10A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,GSK1210151A,,ED20 and 1/10 of it,24
PRJNA379584,GSK461364.6.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,GSK461364,,ED20 and 1/10 of it,6
PRJNA379584,GSK461364.24.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,GSK461364,,ED20 and 1/10 of it,24
PRJNA379584,GSK461364.6.10B,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,GSK461364,,ED20 and 1/10 of it,6
PRJNA379584,GSK461364.24.10B,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,GSK461364,,ED20 and 1/10 of it,24
PRJNA379584,GW_405833.6.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,GW_405833,,ED20 and 1/10 of it,6
PRJNA379584,GW_405833.24.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,GW_405833,,ED20 and 1/10 of it,24
PRJNA379584,HMN_214.6.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,HMN_214,,ED20 and 1/10 of it,6
PRJNA379584,HMN_214.24.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,HMN_214,,ED20 and 1/10 of it,24
PRJNA379584,Ibrutinib.6.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Ibrutinib,,ED20 and 1/10 of it,6
PRJNA379584,Ibrutinib.24.7,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Ibrutinib,,ED20 and 1/10 of it,24
PRJNA379584,Imatinib.6.1,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Imatinib,,ED20 and 1/10 of it,6
PRJNA379584,Imatinib.24.1,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Imatinib,,ED20 and 1/10 of it,24
PRJNA379584,INC280.6.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,INC280,,ED20 and 1/10 of it,6
PRJNA379584,INC280.24.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,INC280,,ED20 and 1/10 of it,24
PRJNA379584,Istradefylline.6.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Istradefylline,,ED20 and 1/10 of it,6
PRJNA379584,Istradefylline.24.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Istradefylline,,ED20 and 1/10 of it,24
PRJNA379584,JNJ_26854165.6.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,JNJ_26854165,,ED20 and 1/10 of it,6
PRJNA379584,JNJ_26854165.24.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,JNJ_26854165,,ED20 and 1/10 of it,24
PRJNA379584,KHS101.6.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,KHS101,,ED20 and 1/10 of it,6
PRJNA379584,KHS101.24.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,KHS101,,ED20 and 1/10 of it,24
PRJNA379584,KU_0063794.6.11B,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,KU_0063794,,ED20 and 1/10 of it,6
PRJNA379584,KU_0063794.24.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,KU_0063794,,ED20 and 1/10 of it,24
PRJNA379584,KW_2449.6.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,KW_2449,,ED20 and 1/10 of it,6
PRJNA379584,KW_2449.24.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,KW_2449,,ED20 and 1/10 of it,24
PRJNA379584,KX2_391.6.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,KX2_391,,ED20 and 1/10 of it,6
PRJNA379584,KX2_391.24.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,KX2_391,,ED20 and 1/10 of it,24
PRJNA379584,LDK378.6.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,LDK378,,ED20 and 1/10 of it,6
PRJNA379584,LDK378.24.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,LDK378,,ED20 and 1/10 of it,24
PRJNA379584,LEE011.6.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,LEE011,,ED20 and 1/10 of it,6
PRJNA379584,LEE011.24.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,LEE011,,ED20 and 1/10 of it,24
PRJNA379584,Leptomycin_B_in_Ethanol.6.12C,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Leptomycin_B_in_Ethanol,,ED20 and 1/10 of it,6
PRJNA379584,Leptomycin_B_in_Ethanol.24.12C,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Leptomycin_B_in_Ethanol,,ED20 and 1/10 of it,24
PRJNA379584,Linifanib.6.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Linifanib,,ED20 and 1/10 of it,6
PRJNA379584,Linifanib.24.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Linifanib,,ED20 and 1/10 of it,24
PRJNA379584,LY_2183240.6.11B,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,LY_2183240,,ED20 and 1/10 of it,6
PRJNA379584,LY_2183240.24.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,LY_2183240,,ED20 and 1/10 of it,24
PRJNA379584,Manumycin_A.6.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Manumycin_A,,ED20 and 1/10 of it,6
PRJNA379584,Manumycin_A.24.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Manumycin_A,,ED20 and 1/10 of it,24
PRJNA379584,Manumycin_A.6.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Manumycin_A,,ED20 and 1/10 of it,6
PRJNA379584,Methylstat.6.2,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Methylstat,,ED20 and 1/10 of it,6
PRJNA379584,Methylstat.24.3,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Methylstat,,ED20 and 1/10 of it,24
PRJNA379584,MG_132.6.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,MG_132,,ED20 and 1/10 of it,6
PRJNA379584,MG_132.24.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,MG_132,,ED20 and 1/10 of it,24
PRJNA379584,Mithramycin_A.6.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Mithramycin_A,,ED20 and 1/10 of it,6
PRJNA379584,Mithramycin_A.24.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Mithramycin_A,,ED20 and 1/10 of it,24
PRJNA379584,Mitomycin_C.6.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Mitomycin_C,,ED20 and 1/10 of it,6
PRJNA379584,Mitomycin_C.24.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Mitomycin_C,,ED20 and 1/10 of it,24
PRJNA379584,MK_1775.6.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,MK_1775,,ED20 and 1/10 of it,6
PRJNA379584,MK_1775.24.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,MK_1775,,ED20 and 1/10 of it,24
PRJNA379584,MK_2206.6.1,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,MK_2206,,ED20 and 1/10 of it,6
PRJNA379584,MK_2206.24.1,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,MK_2206,,ED20 and 1/10 of it,24
PRJNA379584,ML210.6.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,ML210,,ED20 and 1/10 of it,6
PRJNA379584,ML210.24.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,ML210,,ED20 and 1/10 of it,24
PRJNA379584,MST_312.6.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,MST_312,,ED20 and 1/10 of it,6
PRJNA379584,MST_312.24.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,MST_312,,ED20 and 1/10 of it,24
PRJNA379584,Necrosulfonamide.6.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Necrosulfonamide,,ED20 and 1/10 of it,6
PRJNA379584,Necrosulfonamide.24.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Necrosulfonamide,,ED20 and 1/10 of it,24
PRJNA379584,Neratinib.6.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Neratinib,,ED20 and 1/10 of it,6
PRJNA379584,Neratinib.24.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Neratinib,,ED20 and 1/10 of it,24
PRJNA379584,NIlotinib.6.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,NIlotinib,,ED20 and 1/10 of it,6
PRJNA379584,NIlotinib.24.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,NIlotinib,,ED20 and 1/10 of it,24
PRJNA379584,Nutlin_3.6.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Nutlin_3,,ED20 and 1/10 of it,6
PRJNA379584,Nutlin_3.24.8,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Nutlin_3,,ED20 and 1/10 of it,24
PRJNA379584,NVP_231.6.2,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,NVP_231,,ED20 and 1/10 of it,6
PRJNA379584,NVP_231.24.3,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,NVP_231,,ED20 and 1/10 of it,24
PRJNA379584,Obatoclax.6.2,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Obatoclax,,ED20 and 1/10 of it,6
PRJNA379584,Obatoclax.24.3,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Obatoclax,,ED20 and 1/10 of it,24
PRJNA379584,PAC_1.6.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,PAC_1,,ED20 and 1/10 of it,6
PRJNA379584,PAC_1.24.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,PAC_1,,ED20 and 1/10 of it,24
PRJNA379584,Paclitaxel.6.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Paclitaxel,,ED20 and 1/10 of it,6
PRJNA379584,Paclitaxel.24.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Paclitaxel,,ED20 and 1/10 of it,24
PRJNA379584,Panobinostat.6.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Panobinostat,,ED20 and 1/10 of it,6
PRJNA379584,Panobinostat.24.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Panobinostat,,ED20 and 1/10 of it,24
PRJNA379584,Parbendazole.6.11A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Parbendazole,,ED20 and 1/10 of it,6
PRJNA379584,Parbendazole.24.11A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Parbendazole,,ED20 and 1/10 of it,24
PRJNA379584,Parthenolide.6.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Parthenolide,,ED20 and 1/10 of it,6
PRJNA379584,Parthenolide.24.4,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Parthenolide,,ED20 and 1/10 of it,24
PRJNA379584,PF_3758309.6.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,PF_3758309,,ED20 and 1/10 of it,6
PRJNA379584,PF_3758309.24.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,PF_3758309,,ED20 and 1/10 of it,24
PRJNA379584,PF_573228.6.11B,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,PF_573228,,ED20 and 1/10 of it,6
PRJNA379584,PF_573228.24.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,PF_573228,,ED20 and 1/10 of it,24
PRJNA379584,PHA_665752.6.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,PHA_665752,,ED20 and 1/10 of it,6
PRJNA379584,PHA_665752.24.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,PHA_665752,,ED20 and 1/10 of it,24
PRJNA379584,Piperlongumine.6.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Piperlongumine,,ED20 and 1/10 of it,6
PRJNA379584,Piperlongumine.24.5,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Piperlongumine,,ED20 and 1/10 of it,24
PRJNA379584,Piperlongumine.6.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Piperlongumine,,ED20 and 1/10 of it,6
PRJNA379584,PKC412.6.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,PKC412,,ED20 and 1/10 of it,6
PRJNA379584,PKC412.24.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,PKC412,,ED20 and 1/10 of it,24
PRJNA379584,Pluripotin.6.10B,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Pluripotin,,ED20 and 1/10 of it,6
PRJNA379584,Pluripotin.24.10B,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Pluripotin,,ED20 and 1/10 of it,24
PRJNA379584,Pluripotin.24.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Pluripotin,,ED20 and 1/10 of it,24
PRJNA379584,RAD001.6.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,RAD001,,ED20 and 1/10 of it,6
PRJNA379584,RAD001.24.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,RAD001,,ED20 and 1/10 of it,24
PRJNA379584,Rigosertib.6.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Rigosertib,,ED20 and 1/10 of it,6
PRJNA379584,Rigosertib.24.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Rigosertib,,ED20 and 1/10 of it,24
PRJNA379584,Rosiglitazone.6.11A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Rosiglitazone,,ED20 and 1/10 of it,6
PRJNA379584,Rosiglitazone.24.11A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Rosiglitazone,,ED20 and 1/10 of it,24
PRJNA379584,SB_225002.6.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,SB_225002,,ED20 and 1/10 of it,6
PRJNA379584,SB_225002.24.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,SB_225002,,ED20 and 1/10 of it,24
PRJNA379584,SB_743921.6.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,SB_743921,,ED20 and 1/10 of it,6
PRJNA379584,SB_743921.24.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,SB_743921,,ED20 and 1/10 of it,24
PRJNA379584,SCH_529074.6.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,SCH_529074,,ED20 and 1/10 of it,6
PRJNA379584,SCH_529074.24.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,SCH_529074,,ED20 and 1/10 of it,24
PRJNA379584,SCH_79797.6.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,SCH_79797,,ED20 and 1/10 of it,6
PRJNA379584,SCH_79797.24.9,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,SCH_79797,,ED20 and 1/10 of it,24
PRJNA379584,SCH_79797.24.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,SCH_79797,,ED20 and 1/10 of it,24
PRJNA379584,SNX_2112.6.2,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,SNX_2112,,ED20 and 1/10 of it,6
PRJNA379584,SNX_2112.24.3,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,SNX_2112,,ED20 and 1/10 of it,24
PRJNA379584,Sorafenib.6.10B,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Sorafenib,,ED20 and 1/10 of it,6
PRJNA379584,Sorafenib.24.10B,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Sorafenib,,ED20 and 1/10 of it,24
PRJNA379584,SU11274.6.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,SU11274,,ED20 and 1/10 of it,6
PRJNA379584,SU11274.24.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,SU11274,,ED20 and 1/10 of it,24
PRJNA379584,Sunitinib.6.2,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Sunitinib,,ED20 and 1/10 of it,6
PRJNA379584,Sunitinib.24.3,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Sunitinib,,ED20 and 1/10 of it,24
PRJNA379584,Tivantinib.6.1,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Tivantinib,,ED20 and 1/10 of it,6
PRJNA379584,Tivantinib.24.1,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Tivantinib,,ED20 and 1/10 of it,24
PRJNA379584,Topotecan.6.1,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Topotecan,,ED20 and 1/10 of it,6
PRJNA379584,Topotecan.24.1,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Topotecan,,ED20 and 1/10 of it,24
PRJNA379584,TW_37.6.10B,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,TW_37,,ED20 and 1/10 of it,6
PRJNA379584,TW_37.24.10B,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,TW_37,,ED20 and 1/10 of it,24
PRJNA379584,Vincristine.6.11A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Vincristine,,ED20 and 1/10 of it,6
PRJNA379584,Vincristine.24.11A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Vincristine,,ED20 and 1/10 of it,24
PRJNA379584,Vorinostat.6.10B,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Vorinostat,,ED20 and 1/10 of it,6
PRJNA379584,Vorinostat.24.10B,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Vorinostat,,ED20 and 1/10 of it,24
PRJNA379584,x5Zx_7_Oxozeanol.6.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,x5Zx_7_Oxozeanol,,ED20 and 1/10 of it,6
PRJNA379584,x5Zx_7_Oxozeanol.24.6,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,x5Zx_7_Oxozeanol,,ED20 and 1/10 of it,24
PRJNA379584,Y_27632.6.11A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Y_27632,,ED20 and 1/10 of it,6
PRJNA379584,Y_27632.24.11A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Y_27632,,ED20 and 1/10 of it,24
PRJNA379584,Y_27632.6.12A,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,Y_27632,,ED20 and 1/10 of it,6
PRJNA379584,YK_4_279.6.1,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,YK_4_279,,ED20 and 1/10 of it,6
PRJNA379584,YK_4_279.24.1,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,YK_4_279,,ED20 and 1/10 of it,24
PRJNA379584,YM_155.6.2,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,YM_155,,ED20 and 1/10 of it,6
PRJNA379584,YM_155.24.3,H-STS NET,patient-derived hepatic metastasis,terminal ileum,Carcinoid tumor,YM_155,,ED20 and 1/10 of it,24
PRJNA387040,etoposide,IMR90,fibroblast,lung,Normal,Etoposide,DNA topoisomerase II (TOP2),100uM,48
PRJNA387040,ko_eto,IMR90_shNTC,fibroblast,lung,Normal,Etoposide,DNA topoisomerase II (TOP2),100uM,48
PRJNA387040,wt_eto,IMR90_shCGAS,fibroblast,lung,Normal,Etoposide,DNA topoisomerase II (TOP2),100uM,48
PRJNA391270,a498_4gy,A498,epithelial,kidney,Carcinoma,4Gy IR,radiation,,3
PRJNA391270,a549_4gy,A459,epithelial,lung,Carcinoma,4Gy IR,radiation,,3
PRJNA391270,gy4.3hr,Combined Cell Lines,,,,4Gy IR,radiation,,3
PRJNA391270,h460_4gy,H460,epithelial,lung,Carcinoma,4Gy IR,radiation,,3
PRJNA391270,hct116_4gy,HCT116,epithelial,colon,Carcinoma; Colorectal,4Gy IR,radiation,,3
PRJNA391270,lox_4gy,LOXIMVI,epithelial,melanoma,Malignant Melanoma,4Gy IR,radiation,,3
PRJNA391270,malme3_4gy,MALME3M,fibroblast,melanoma,Malignant Melanoma,4Gy IR,radiation,,3
PRJNA391270,skmel5_4gy,SKMEL5,melanocyte,melanoma,Malignant Melanoma,4Gy IR,radiation,,3
PRJNA391270,u2os_4gy,U2OS,epithelial,bone,Osteosarcoma,4Gy IR,radiation,,3
PRJNA391270,uacc257_4gy,UACC257,epithelial,melanoma,Malignant Melanoma,4Gy IR,radiation,,3
PRJNA391270,uo31_4gy,UO31,epithelial,kidney,Carcinoma,4Gy IR,radiation,,3
PRJNA391270,mcf7_4gy,MCF7,epithelial,breast,Adenocarcinoma,4Gy IR + Decitabine,radiation +  Human Deoxyribonucleic acid (hDNA),2uM,3
PRJNA391270,a549_nut,A459,epithelial,lung,Carcinoma,Nutlin3A,Cellular tumor antigen p53 (TP53); Mdm2 messenger RNA (MDM2 mRNA),5uM,NA
PRJNA391270,a549_tgfb_nut,A459,epithelial,lung,Carcinoma,Nutlin3A + TGFB,Cellular tumor antigen p53 (TP53); Mdm2 messenger RNA (MDM2 mRNA),5uM + 2.5ng/ml,120
PRJNA391270,a549_tgfb,A459,epithelial,lung,Carcinoma,TGFB,Transforming growth factor beta (TGF-Î²),2.5ng/ml,120
PRJNA392914,carboplatin.50uM_72hr,PC9,epithelial,lung,Carcinoma,Carboplatin,Human Deoxyribonucleic acid (hDNA),50uM,72
PRJNA392914,erlotinib.1uM_24hr,PC9,epithelial,lung,Carcinoma,Erlotinib,Epidermal growth factor receptor (EGFR),1um,24
PRJNA392914,dtp_tsa,PC9 DTP,epithelial,lung,Carcinoma,TSA,Histone deacetylase (HDAC),50nM,5
PRJNA392914,tsa.50nM_5hr,PC9,epithelial,lung,Carcinoma,TSA,Histone deacetylase (HDAC),50nM,5
PRJNA392914,dtp,PC9,epithelial,lung,Carcinoma,,,,
PRJNA395584,HL_60.BI00894999.35nM,HL-60,promyeloblast,myeloid,acute promyelocytic leukemia,BI 00894999,Bromodomain and extraterminal domain protein (BET),35nM,
PRJNA395584,KASUMI_1.BI00894999.35nM,Kasumi-1,myeloblast,myeloid,Acute myeloblastic leukemia,BI 00894999,Bromodomain and extraterminal domain protein (BET),35nM,
PRJNA395584,MOLM_13.BI00894999.35nM,MOLM13,myeloblast,myeloid,Acute myeloid leukemia,BI 00894999,Bromodomain and extraterminal domain protein (BET),35nM,
PRJNA395584,MV_4_11_B.BI00894999.1000nM,MV-4-11B,lymphoblast,myeloid,Biphenotypic B Myelomonocytic Leukemia,BI 00894999,Bromodomain and extraterminal domain protein (BET),1000nM,
PRJNA395584,MV_4_11_B.BI00894999.100nM,MV-4-11B,lymphoblast,myeloid,Biphenotypic B Myelomonocytic Leukemia,BI 00894999,Bromodomain and extraterminal domain protein (BET),100nM,
PRJNA395584,MV_4_11_B.BI00894999.1nM,MV-4-11B,lymphoblast,myeloid,Biphenotypic B Myelomonocytic Leukemia,BI 00894999,Bromodomain and extraterminal domain protein (BET),1nM,
PRJNA395584,MV_4_11_B.BI00894999.35nM,MV-4-11B,lymphoblast,myeloid,Biphenotypic B Myelomonocytic Leukemia,BI 00894999,Bromodomain and extraterminal domain protein (BET),35nM,
PRJNA395584,NCI_H2171.BI00894999.100nM,NCI-H2171,lymphoblast,lung,Carcinoma,BI 00894999,Bromodomain and extraterminal domain protein (BET),100nM,
PRJNA395584,OCI_AML3.BI00894999.35nM,OCI-AML3,myeloblast,myeloid,Acute myeloid leukemia,BI 00894999,Bromodomain and extraterminal domain protein (BET),35nM,
PRJNA395584,MV_4_11_B.BI00894999_EX00101218.35nM_5uM,MV-4-11B,lymphoblast,myeloid,Biphenotypic B Myelomonocytic Leukemia,BI 00894999_EX00101218,Bromodomain and extraterminal domain protein (BET),35nM + 5uM,
PRJNA395584,MV_4_11_B.EX00101218.5uM,MV-4-11B,lymphoblast,myeloid,Biphenotypic B Myelomonocytic Leukemia,EX00101218,Bromodomain and extraterminal domain protein (BET),5uM,
PRJNA400080,BI00894999.1nM.24,MV-4-11B,lymphoblast,myeloid,Biphenotypic B Myelomonocytic Leukemia,BI 00894999,Bromodomain and extraterminal domain protein (BET),1nM,24
PRJNA400080,BI00894999.1nM.4,MV-4-11B,lymphoblast,myeloid,Biphenotypic B Myelomonocytic Leukemia,BI 00894999,Bromodomain and extraterminal domain protein (BET),1nM,4
PRJNA400080,BI00894999.35nM.24,MV-4-11B,lymphoblast,myeloid,Biphenotypic B Myelomonocytic Leukemia,BI 00894999,Bromodomain and extraterminal domain protein (BET),35nM,24
PRJNA400080,BI00894999.35nM.4,MV-4-11B,lymphoblast,myeloid,Biphenotypic B Myelomonocytic Leukemia,BI 00894999,Bromodomain and extraterminal domain protein (BET),35nM,4
PRJNA400080,BI00894999_Volasertib.1nM_20nM.24,MV-4-11B,lymphoblast,myeloid,Biphenotypic B Myelomonocytic Leukemia,BI 00894999 + Volasertib,Bromodomain and extraterminal domain protein (BET);   Polo-like kinase 1 (PLK1),1nM + 20nM,24
PRJNA400080,BI00894999_Volasertib.1nM_20nM.4,MV-4-11B,lymphoblast,myeloid,Biphenotypic B Myelomonocytic Leukemia,BI 00894999 + Volasertib,Bromodomain and extraterminal domain protein (BET);   Polo-like kinase 1 (PLK1),1nM + 20nM,4
PRJNA400080,BI00894999_Volasertib.35nM_20nM.24,MV-4-11B,lymphoblast,myeloid,Biphenotypic B Myelomonocytic Leukemia,BI 00894999 + Volasertib,Bromodomain and extraterminal domain protein (BET);   Polo-like kinase 1 (PLK1),35nM + 20nM,24
PRJNA400080,BI00894999_Volasertib.35nM_20nM.4,MV-4-11B,lymphoblast,myeloid,Biphenotypic B Myelomonocytic Leukemia,BI 00894999 + Volasertib,Bromodomain and extraterminal domain protein (BET);   Polo-like kinase 1 (PLK1),35nM + 20nM,4
PRJNA400080,Volasertib.20nM.24,MV-4-11B,lymphoblast,myeloid,Biphenotypic B Myelomonocytic Leukemia,Volasertib,Polo-like kinase 1 (PLK1),20nM,24
PRJNA400080,Volasertib.20nM.4,MV-4-11B,lymphoblast,myeloid,Biphenotypic B Myelomonocytic Leukemia,Volasertib,Polo-like kinase 1 (PLK1),20nM,4
PRJNA417314,hc29_5fu,HT-29,epithelial,large intestine; colon,Adenocarcinoma,5-FU,Candida Thymidylate synthase (Candi TMP1); Dihydrothymine dehydrogenase (DPYD); TERT messenger RNA (TERT mRNA); Thymidylate synthase messenger RNA (TYMS mRNA),20uM,72
PRJNA422779,G12V.MS275.1,CaCO-2et KRAS G12V,epithelial,large intestine; colon,Adenocarcinoma,MS-275,Histone deacetylase (HDAC); Histone deacetylase 1 (HDAC1),NA,1
PRJNA422779,G12V.MS275.24,CaCO-2et KRAS G12V,epithelial,large intestine; colon,Adenocarcinoma,MS-275,Histone deacetylase (HDAC); Histone deacetylase 1 (HDAC1),NA,24
PRJNA422779,G12V.MS275.6,CaCO-2et KRAS G12V,epithelial,large intestine; colon,Adenocarcinoma,MS-275,Histone deacetylase (HDAC); Histone deacetylase 1 (HDAC1),NA,6
PRJNA422779,G12V.MS275.72,CaCO-2et KRAS G12V,epithelial,large intestine; colon,Adenocarcinoma,MS-275,Histone deacetylase (HDAC); Histone deacetylase 1 (HDAC1),NA,72
PRJNA422779,WT.MS275.1,CaCO-2et KRAS WT,epithelial,large intestine; colon,Adenocarcinoma,MS-275,Histone deacetylase (HDAC); Histone deacetylase 1 (HDAC1),NA,1
PRJNA422779,WT.MS275.24,CaCO-2et KRAS WT,epithelial,large intestine; colon,Adenocarcinoma,MS-275,Histone deacetylase (HDAC); Histone deacetylase 1 (HDAC1),NA,24
PRJNA422779,WT.MS275.6,CaCO-2et KRAS WT,epithelial,large intestine; colon,Adenocarcinoma,MS-275,Histone deacetylase (HDAC); Histone deacetylase 1 (HDAC1),NA,6
PRJNA422779,WT.MS275.72,CaCO-2et KRAS WT,epithelial,large intestine; colon,Adenocarcinoma,MS-275,Histone deacetylase (HDAC); Histone deacetylase 1 (HDAC1),NA,72
PRJNA471642,SD6.125nm.24hr,CLL,lymphoblast,lymphoid,Chronic lymphocytic leukemia,SD6,Splicing factor modulator,125nM,24
PRJNA471642,SD6.125nm.2hr,CLL,lymphoblast,lymphoid,Chronic lymphocytic leukemia,SD6,Splicing factor modulator,125nM,2
PRJNA471642,SD6.125nm.6hr,CLL,lymphoblast,lymphoid,Chronic lymphocytic leukemia,SD6,Splicing factor modulator,125nM,6
PRJNA471642,mec1_vs_gm12878,MEC1,lymphoblast,lymphoid,Chronic lymphocytic leukemia,,,,
PRJNA474537,CC122.24,OSU-CLL,EBV-transformed lymphoblastoid cell line,lymphoid,Chronic lymphocytic leukemia,CC-122,Modulates cereblon E3 ligase activity,1uM,24
PRJNA474537,CC122.5,OSU-CLL,EBV-transformed lymphoblastoid cell line,lymphoid,Chronic lymphocytic leukemia,CC-122,Modulates cereblon E3 ligase activity,0.1uM,5
PRJNA474537,LEN.24,OSU-CLL,EBV-transformed lymphoblastoid cell line,lymphoid,Chronic lymphocytic leukemia,Lenalidomide,Tumor necrosis factor (TNF),1uM,24
PRJNA474537,LEN.5,OSU-CLL,EBV-transformed lymphoblastoid cell line,lymphoid,Chronic lymphocytic leukemia,Lenalidomide,Tumor necrosis factor (TNF),1uM,5
PRJNA477352,j4.thz1_250nM_6hr,HBL-2 MCL ABT-199 DTP,epithelial,lymphoma,Mantle cell lymphoma,THZ1,Cyclin-dependent kinase 7 (CDK7),250nM,6
PRJNA477352,j4.thz1_50nM_6hr,HBL-2 MCL ABT-199 DTP,epithelial,lymphoma,Mantle cell lymphoma,THZ1,Cyclin-dependent kinase 7 (CDK7),50nM,6
PRJNA477352,l10.thz1_250nM_6hr,HBL-2 MCL ABT-199 DTP,epithelial,lymphoma,Mantle cell lymphoma,THZ1,Cyclin-dependent kinase 7 (CDK7),250nM,6
PRJNA477352,l10.thz1_50nM_6hr,HBL-2 MCL ABT-199 DTP,epithelial,lymphoma,Mantle cell lymphoma,THZ1,Cyclin-dependent kinase 7 (CDK7),50nM,6
PRJNA477352,l20.thz1_250nM_6hr,HBL-2 MCL ABT-199 DTP,epithelial,lymphoma,Mantle cell lymphoma,THZ1,Cyclin-dependent kinase 7 (CDK7),250nM,6
PRJNA477352,l20.thz1_50nM_6hr,HBL-2 MCL ABT-199 DTP,epithelial,lymphoma,Mantle cell lymphoma,THZ1,Cyclin-dependent kinase 7 (CDK7),50nM,6
PRJNA477352,par.thz1_250nM_6hr,HBL-2 MCL ABT-199 DTP,epithelial,lymphoma,Mantle cell lymphoma,THZ1,Cyclin-dependent kinase 7 (CDK7),250nM,6
PRJNA477352,par.thz1_50nM_6hr,HBL-2 MCL ABT-199 DTP,epithelial,lymphoma,Mantle cell lymphoma,THZ1,Cyclin-dependent kinase 7 (CDK7),50nM,6
PRJNA477352,thz1_250nM_6hr,HBL-2 MCL ABT-199 DTP,epithelial,lymphoma,Mantle cell lymphoma,THZ1,Cyclin-dependent kinase 7 (CDK7),250nM,6
PRJNA477352,thz1_50nM_6hr,HBL-2 MCL ABT-199 DTP,epithelial,lymphoma,Mantle cell lymphoma,THZ1,Cyclin-dependent kinase 7 (CDK7),50nM,6
PRJNA479415,venetoclax_azacitidine_6hr,AML,primary human cells,myeloid,Acute myeloid leukemia,Venetoclax + Azacitidine,Apoptosis regulator Bcl-2 (BCL-2); DNA [cytosine-5]-methyltransferase (DNMT),500nM + 2.5uM,6
PRJNA497893,hpv16,NOK,epithelial,keratinocytes,Normal Oral Keratinocytes,,,,
PRJNA497893,hpv16_e2,NOK,epithelial,keratinocytes,Normal Oral Keratinocytes,,,,
PRJNA533647,PCIA_Bu,HFSC,primary human cells,skin,Permanent Chemothrapy Induced Alopecia,Busulfan,Alkylating agent,20mg/kg/day,
PRJNA533647,PCIA_BuCy,HFSC,primary human cells,skin,Permanent Chemothrapy Induced Alopecia,Busulfan + Cyclophosphamide,Alkylating agent,20mg/kg/day + 100mg/kg/day,
PRJNA555350,doxorubicin,HEL,myeloblast,myeloid,Erythroleukemia,Doxorubicin,DNA topoisomerase II (TOP2); TERT messenger RNA (TERT mRNA),3mg/kg,120
PRJNA555350,doxorubicin_cytabine,HEL,myeloblast,myeloid,Erythroleukemia,Doxorubicin + Cytarabine,DNA topoisomerase II (TOP2); TERT messenger RNA (TERT mRNA); Herpes simplex virus DNA polymerase UL30 (HSV UL30),3mg/kg + 100mg/kg,120
PRJNA555350,doxorubicin_cytabine_decitabine,HEL,myeloblast,myeloid,Erythroleukemia,Doxorubicin + Cytarabine + Decitibine,DNA topoisomerase II (TOP2); TERT messenger RNA (TERT mRNA); Herpes simplex virus DNA polymerase UL30 (HSV UL30); Human Deoxyribonucleic acid (hDNA),3mg/kg + 100mg/kg + 0.5mg/kg,120
PRJNA560975,tedizolid.5uM.4d,MOLM13,myeloblast,myeloid,AML FLT3-ITD,Tedizolid,Bacterial 50S ribosomal RNA (Bact 50S rRNA),5uM,96
PRJNA560975,venetoclax.500nM.4d,MOLM13,myeloblast,myeloid,AML FLT3-ITD,Venetoclax,Apoptosis regulator Bcl-2 (BCL-2),500nM,96
PRJNA560975,venetoclax.500nM_tedizolid.5uM.4d,MOLM13,myeloblast,myeloid,AML FLT3-ITD,Venetoclax + Tedizolid,Apoptosis regulator Bcl-2 (BCL-2); Bacterial 50S ribosomal RNA (Bact 50S rRNA),500nM + 5uM,96
PRJNA596778,dac,786-0,epithelial,kidney,Adenocarcinoma,Decitabine,Human Deoxyribonucleic acid (hDNA),300/100nM,120
PRJNA596778,dac_100nM.786,786-0,epithelial,kidney,Adenocarcinoma,Decitabine,Human Deoxyribonucleic acid (hDNA),100nM,120
PRJNA596778,dac_300nM.786,786-0,epithelial,kidney,Adenocarcinoma,Decitabine,Human Deoxyribonucleic acid (hDNA),300nM,120
PRJNA596778,dac.100nM,786-0,epithelial,kidney,Adenocarcinoma,Decitabine,Human Deoxyribonucleic acid (hDNA),100nM,120
PRJNA596778,dac.300nM,786-0,epithelial,kidney,Adenocarcinoma,Decitabine,Human Deoxyribonucleic acid (hDNA),300nM,120
PRJNA596778,HKC.dac_100nM,HKC,epithelial,kidney,Adenocarcinoma,Decitabine,Human Deoxyribonucleic acid (hDNA),100nM,120
PRJNA596778,HKC.dac_300nM,HKC,epithelial,kidney,Adenocarcinoma,Decitabine,Human Deoxyribonucleic acid (hDNA),300nM,120
PRJNA603369,abbv075.100nM,AML,primary human cells,myeloid,AML,ABBV-075,Bromodomain-containing protein 2 (BRD2); Bromodomain-containing protein 3 (BRD3); Bromodomain-containing protein 4 (BRD4),100nM,24
PRJNA603369,kasumi.abbv075.100nM,Kasumi-1,myeloblast,myeloid,AML,ABBV-075,Bromodomain-containing protein 2 (BRD2); Bromodomain-containing protein 3 (BRD3); Bromodomain-containing protein 4 (BRD4),100nM,24
PRJNA603369,mv411.abbv075.100nM,MV-4-11,lymphoblast,myeloid,AML,ABBV-075,Bromodomain-containing protein 2 (BRD2); Bromodomain-containing protein 3 (BRD3); Bromodomain-containing protein 4 (BRD4),100nM,24
PRJNA603369,nci_h1299.abbv075.100nM,NCI-H1299,epithelial,lung,Carcinoma,ABBV-075,Bromodomain-containing protein 2 (BRD2); Bromodomain-containing protein 3 (BRD3); Bromodomain-containing protein 4 (BRD4),100nM,24
PRJNA603369,skm.abbv075.100nM,SKM-1,myeloblast,myeloid,AML,ABBV-075,Bromodomain-containing protein 2 (BRD2); Bromodomain-containing protein 3 (BRD3); Bromodomain-containing protein 4 (BRD4),100nM,24
PRJNA603369,abbv744.200nM,AML,myeloblast,myeloid,AML,ABBV-744,Bromodomain-containing protein 2 (BRD2); Bromodomain-containing protein 3 (BRD3); Bromodomain-containing protein 4 (BRD4),200nM,24
PRJNA603369,kasumi.abbv744.200nM,Kasumi-1,myeloblast,myeloid,AML,ABBV-744,Bromodomain-containing protein 2 (BRD2); Bromodomain-containing protein 3 (BRD3); Bromodomain-containing protein 4 (BRD4),200nM,24
PRJNA603369,mv411.abbv744.200nM,MV-4-11,myeloblast,myeloid,AML,ABBV-744,Bromodomain-containing protein 2 (BRD2); Bromodomain-containing protein 3 (BRD3); Bromodomain-containing protein 4 (BRD4),200nM,24
PRJNA603369,nci_h1299.abbv744.200nM,NCI-H1299,epithelial,lung,Carcinoma,ABBV-744,Bromodomain-containing protein 2 (BRD2); Bromodomain-containing protein 3 (BRD3); Bromodomain-containing protein 4 (BRD4),200nM,24
PRJNA603369,skm.abbv744.200nM,SKM-1,myeloblast,myeloid,AML,ABBV-744,Bromodomain-containing protein 2 (BRD2); Bromodomain-containing protein 3 (BRD3); Bromodomain-containing protein 4 (BRD4),200nM,24
PRJNA607909,dac,LUAD,,lung,,Decitabine,Human Deoxyribonucleic acid (hDNA),100nM,72
PRJNA610784,Azacitidine,IDH1mut BM,myeloblast,myeloid,AML,Azacitidine,DNA [cytosine-5]-methyltransferase (DNMT),500nM,96
PRJNA610784,BAY1436032,IDH1mut BM,myeloblast,myeloid,AML,BAY1436032,Mutated oxalosuccinate decarboxylase (mIDH1),50nM,120
PRJNA610784,BAY1436032_Azacitidine_seq,IDH1mut BM,myeloblast,myeloid,AML,BAY1436032_Azacitidine_seq,Mutated oxalosuccinate decarboxylase (mIDH1),50nM+500nM,216
PRJNA610784,BAY1436032_Azacitidine_sim,IDH1mut BM,myeloblast,myeloid,AML,BAY1436032_Azacitidine_sim,Mutated oxalosuccinate decarboxylase (mIDH1),50nM+500nM,120
PRJNA614994,trc105_vs_igg,AML,myeloblast,myeloid,AML,TRC105,Endoglin CD105 (ENG),NA,NA
PRJNA636096,MCC,BLCA,epithelial,bladder,Bladder Carcinoma,Mitomycin C,Human Deoxyribonucleic acid (hDNA),30uM,48
PRJNA636096,MCC.5637,5637,epithelial,bladder,Bladder Carcinoma,Mitomycin C,Human Deoxyribonucleic acid (hDNA),30uM,48
PRJNA636096,MCC.CLS_439,CLS-439,epithelial,bladder,Bladder Carcinoma,Mitomycin C,Human Deoxyribonucleic acid (hDNA),30uM,48
PRJNA636096,MCC.T24,T24,epithelial,bladder,Transitional cell carcinoma,Mitomycin C,Human Deoxyribonucleic acid (hDNA),30uM,48
PRJNA636096,MCC.TCC_SUP,TCC-SUP,epithelial,bladder,Carcinoma,Mitomycin C,Human Deoxyribonucleic acid (hDNA),30uM,48
PRJNA641077,x1874,HCT116,epithelial,large intestine; colon,Carcinoma,GB1874,Î²-catenin (Î²-cat)-TCF4 protein-protein interaction (PPI),50uM,24
PRJNA641077,x6853,HCT116,epithelial,large intestine; colon,Carcinoma,GB6853,Î²-catenin (Î²-cat)-TCF4 protein-protein interaction (PPI),50uM,24
PRJNA641077,x8679,HCT116,epithelial,large intestine; colon,Carcinoma,GB8679,Î²-catenin (Î²-cat)-TCF4 protein-protein interaction (PPI),50uM,24
PRJNA641077,iCRT3,HCT116,epithelial,large intestine; colon,Carcinoma,iCRT3,Wnt/Î²-catenin antagonist,20nM,48
PRJNA641077,siCTNNB1,HCT116,epithelial,large intestine; colon,Carcinoma,siCTNNB1,siCTNNB1,20nM,48
PRJNA641077,siNeg,HCT116,epithelial,large intestine; colon,Carcinoma,siNeg,siNeg,20nM,48
PRJNA642730,dac,GSC,epithelial,brain,Glioblastoma,Decitabine,Human Deoxyribonucleic acid (hDNA),NA,NA
PRJNA642730,NCH1681.dac,NCH1681,epithelial,brain,Glioblastoma,Decitabine,Human Deoxyribonucleic acid (hDNA),NA,NA
PRJNA642730,NCH612.dac,NCH612,epithelial,brain,Glioblastoma,Decitabine,Human Deoxyribonucleic acid (hDNA),NA,NA
PRJNA642730,SU_AO3.dac,SU-AO3,epithelial,brain,Glioblastoma,Decitabine,Human Deoxyribonucleic acid (hDNA),NA,NA
PRJNA642730,TS603.dac,TS603,epithelial,brain,Glioblastoma,Decitabine,Human Deoxyribonucleic acid (hDNA),NA,NA
PRJNA649431,dac,T-ALL,lymphoblast,lymphoid,ALL,Decitabine,Human Deoxyribonucleic acid (hDNA),NA,NA
PRJNA649431,PDX_TALL1.dac,T-ALL1,lymphoblast,lymphoid,ALL,Decitabine,Human Deoxyribonucleic acid (hDNA),NA,NA
PRJNA649431,PDX_TALL2.dac,T-ALL2,lymphoblast,lymphoid,ALL,Decitabine,Human Deoxyribonucleic acid (hDNA),NA,NA
PRJNA649432,dac,T-ALL,lymphoblast,lymphoid,ALL,Decitabine,Human Deoxyribonucleic acid (hDNA),NA,NA
PRJNA649432,Loucy.dac,Loucy,lymphoblast,lymphoid,ALL,Decitabine,Human Deoxyribonucleic acid (hDNA),NA,NA
PRJNA649432,MOLT_16.dac,MOLT,lymphoblast,lymphoid,ALL,Decitabine,Human Deoxyribonucleic acid (hDNA),NA,NA
PRJNA649432,PEER.dac,PEER,lymphoblast,lymphoid,ALL,Decitabine,Human Deoxyribonucleic acid (hDNA),NA,NA
PRJNA649432,PER_117.dac,PER,lymphoblast,lymphoid,ALL,Decitabine,Human Deoxyribonucleic acid (hDNA),NA,NA
PRJNA649432,TALL_1.dac,T-ALL1,lymphoblast,lymphoid,ALL,Decitabine,Human Deoxyribonucleic acid (hDNA),NA,NA
PRJNA657045,Till_CAR.dac_14d_vs_7d,CAR T,PBMC,blood,,Decitabine,Human Deoxyribonucleic acid (hDNA),NA,336
PRJNA657045,Till_dCAR.dac_14d_vs_7d,CAR T,PBMC,blood,,Decitabine,Human Deoxyribonucleic acid (hDNA),NA,336
PRJNA657045,dCAR.dac_Raij_vs_dac,CAR,PBMC,blood,,Decitabine + Raij coculture,Human Deoxyribonucleic acid (hDNA),NA,336
PRJNA657045,CAR.Raij,CAR,PBMC,blood,,Raij coculture,,NA,336
PRJNA657067,Cotyledon_orbiculata_extract,HCT116,epithelial,large intestine; colon,Carcinoma,Cotyledon_orbiculata_extract,Splice Modulator,Cotyledon orbiculata extract,
PRJNA670855,sbi756.4hr,non-Hogkin lymphoma,lymphoblast,lymph node,Large cell Lymphoma,SBI-756,eIF4G1 inhibitor,NA,4
PRJNA670901,azacitidine_125nM,TCL,lymphoblast,lymphoid,T-lymphoma,Azacitidine,DNA [cytosine-5]-methyltransferase (DNMT),125nM,NA
PRJNA670901,azacitidine_250nM,TCL,lymphoblast,lymphoid,T-lymphoma,Azacitidine,DNA [cytosine-5]-methyltransferase (DNMT),250nM,NA
PRJNA670901,azacitidine_50nM,TCL,lymphoblast,lymphoid,T-lymphoma,Azacitidine,DNA [cytosine-5]-methyltransferase (DNMT),50nM,NA
PRJNA670901,HH.azacitidine,HH,lymphoblast,lymphoid,T-lymphoma,Azacitidine,DNA [cytosine-5]-methyltransferase (DNMT),50/125/250nM,NA
PRJNA670901,HH.azacitidine_125nM,HH,lymphoblast,lymphoid,T-lymphoma,Azacitidine,DNA [cytosine-5]-methyltransferase (DNMT),125nM,NA
PRJNA670901,HH.azacitidine_250nM,HH,lymphoblast,lymphoid,T-lymphoma,Azacitidine,DNA [cytosine-5]-methyltransferase (DNMT),250nM,NA
PRJNA670901,HH.azacitidine_50nM,HH,lymphoblast,lymphoid,T-lymphoma,Azacitidine,DNA [cytosine-5]-methyltransferase (DNMT),50nM,NA
PRJNA670901,PF382.azacitidine,PF-382,lymphoblast,lymphoid,T-lymphoma,Azacitidine,DNA [cytosine-5]-methyltransferase (DNMT),50/125/250nM,NA
PRJNA670901,PF382.azacitidine_125nM,PF-382,lymphoblast,lymphoid,T-lymphoma,Azacitidine,DNA [cytosine-5]-methyltransferase (DNMT),125nM,NA
PRJNA670901,PF382.azacitidine_250nM,PF-382,lymphoblast,lymphoid,T-lymphoma,Azacitidine,DNA [cytosine-5]-methyltransferase (DNMT),250nM,NA
PRJNA670901,PF382.azacitidine_500nM,PF-382,lymphoblast,lymphoid,T-lymphoma,Azacitidine,DNA [cytosine-5]-methyltransferase (DNMT),500nM,NA
PRJNA670901,TLOm1.azacitidine,TLOm1,lymphoblast,lymphoid,T-lymphoma,Azacitidine,DNA [cytosine-5]-methyltransferase (DNMT),50/125/250nM,NA
PRJNA670901,TLOm1.azacitidine_125nM,TLOm1,lymphoblast,lymphoid,T-lymphoma,Azacitidine,DNA [cytosine-5]-methyltransferase (DNMT),125nM,NA
PRJNA670901,TLOm1.azacitidine_250nM,TLOm1,lymphoblast,lymphoid,T-lymphoma,Azacitidine,DNA [cytosine-5]-methyltransferase (DNMT),250nM,NA
PRJNA670901,TLOm1.azacitidine_500nM,TLOm1,lymphoblast,lymphoid,T-lymphoma,Azacitidine,DNA [cytosine-5]-methyltransferase (DNMT),500nM,NA
PRJNA670901,dac_12.5nM,TCL,lymphoblast,lymphoid,T-lymphoma,Decitabine,Human Deoxyribonucleic acid (hDNA),12.5nM,NA
PRJNA670901,dac_25nM,TCL,lymphoblast,lymphoid,T-lymphoma,Decitabine,Human Deoxyribonucleic acid (hDNA),25nM,NA
PRJNA670901,dac_5nM,TCL,lymphoblast,lymphoid,T-lymphoma,Decitabine,Human Deoxyribonucleic acid (hDNA),5nM,NA
PRJNA670901,HH.dac,HH,lymphoblast,lymphoid,T-lymphoma,Decitabine,Human Deoxyribonucleic acid (hDNA),5/12.5/25nM,NA
PRJNA670901,HH.dac_12.5nM,HH,lymphoblast,lymphoid,T-lymphoma,Decitabine,Human Deoxyribonucleic acid (hDNA),12.5nM,NA
PRJNA670901,HH.dac_25nM,HH,lymphoblast,lymphoid,T-lymphoma,Decitabine,Human Deoxyribonucleic acid (hDNA),25nM,NA
PRJNA670901,HH.dac_5nM,HH,lymphoblast,lymphoid,T-lymphoma,Decitabine,Human Deoxyribonucleic acid (hDNA),5nM,NA
PRJNA670901,PF382.dac,PF-382,lymphoblast,lymphoid,T-lymphoma,Decitabine,Human Deoxyribonucleic acid (hDNA),5/12.5/25nM,NA
PRJNA670901,PF382.dac_12.5nM,PF-382,lymphoblast,lymphoid,T-lymphoma,Decitabine,Human Deoxyribonucleic acid (hDNA),12.5nM,NA
PRJNA670901,PF382.dac_25nM,PF-382,lymphoblast,lymphoid,T-lymphoma,Decitabine,Human Deoxyribonucleic acid (hDNA),25nM,NA
PRJNA670901,PF382.dac_5nM,PF-382,lymphoblast,lymphoid,T-lymphoma,Decitabine,Human Deoxyribonucleic acid (hDNA),5nM,NA
PRJNA670901,TLOm1.dac,TLOm1,lymphoblast,lymphoid,T-lymphoma,Decitabine,Human Deoxyribonucleic acid (hDNA),5/12.5/25nM,NA
PRJNA670901,TLOm1.dac_12.5nM,TLOm1,lymphoblast,lymphoid,T-lymphoma,Decitabine,Human Deoxyribonucleic acid (hDNA),12.5nM,NA
PRJNA670901,TLOm1.dac_25nM,TLOm1,lymphoblast,lymphoid,T-lymphoma,Decitabine,Human Deoxyribonucleic acid (hDNA),25nM,NA
PRJNA670901,TLOm1.dac_5nM,TLOm1,lymphoblast,lymphoid,T-lymphoma,Decitabine,Human Deoxyribonucleic acid (hDNA),5nM,NA
PRJNA685849,CDDP_50uM_10hr,A375p,epithelial,melanoma,Malignant Melanoma,Cisplatin,Human Deoxyribonucleic acid (hDNA),NA,10
PRJNA685849,CDDP_50uM_20hr,A375p,epithelial,melanoma,Malignant Melanoma,Cisplatin,Human Deoxyribonucleic acid (hDNA),NA,20
PRJNA685849,CDDP_50uM_4hr,A375p,epithelial,melanoma,Malignant Melanoma,Cisplatin,Human Deoxyribonucleic acid (hDNA),NA,4
PRJNA685849,Hypercin_150nM_irradiation_10hr,A375p,epithelial,melanoma,Malignant Melanoma,Hyp-PDT,Enzyme inhibitor; Immunosuppressive agent; Antiviral agent; Radiation-sensitizing agent; Antineoplastic agent,NA,10
PRJNA685849,Hypercin_150nM_irradiation_20hr,A375p,epithelial,melanoma,Malignant Melanoma,Hyp-PDT,Enzyme inhibitor; Immunosuppressive agent; Antiviral agent; Radiation-sensitizing agent; Antineoplastic agent,NA,20
PRJNA685849,Hypercin_150nM_irradiation_4hr,A375p,epithelial,melanoma,Malignant Melanoma,Hyp-PDT,Enzyme inhibitor; Immunosuppressive agent; Antiviral agent; Radiation-sensitizing agent; Antineoplastic agent,NA,4
PRJNA685849,MTX_1um_10hr,A375p,epithelial,melanoma,Malignant Melanoma,Mitoxantrone,DNA topoisomerase II (TOP2),NA,10
PRJNA685849,MTX_1um_20hr,A375p,epithelial,melanoma,Malignant Melanoma,Mitoxantrone,DNA topoisomerase II (TOP2),NA,20
PRJNA685849,MTX_1um_4hr,A375p,epithelial,melanoma,Malignant Melanoma,Mitoxantrone,DNA topoisomerase II (TOP2),NA,4
proa,dac,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Decitabine,Human Deoxyribonucleic acid (hDNA),100nM,48
proa,dac_proa,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Decitabine + Proscillaridin A,Human Deoxyribonucleic acid (hDNA); Enzyme inhibitors; Cardiotonic agents,100nM + 50nM,48
proa,proa,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Proscillaridin A,Enzyme inhibitors; Cardiotonic agents,50nM,48
tak,dac,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Decitabine,Human Deoxyribonucleic acid (hDNA),100nM,96
tak,dac_depsi,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Decitabine + Depsipeptide,Human Deoxyribonucleic acid (hDNA); Histone deacetylase 1 (HDAC1),100nM + 20nM,96
tak,dac_gsk343,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Decitabine + GSK343,Human Deoxyribonucleic acid (hDNA);  Enhancer of zeste homolog 1 (EZH1); Enhancer of zeste homolog 2 (EZH2),100nM + 1uM,96
tak,dac_s2102,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Decitabine + S2101,Human Deoxyribonucleic acid (hDNA); Lysine-Specific Demethylase 1 (LSD1) Inhibitor,100nM + 10uM,96
tak,dac_unc0628,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Decitabine + UNC0638,Human Deoxyribonucleic acid (hDNA); Euchromatic histone-lysine N-methyltransferase 1 (EHMT1); Histone-lysine N-methyltransferase EHMT2 (EHMT2),100nM + 1uM,96
tak,depsi,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Depsipeptide,Histone deacetylase 1 (HDAC1),20nM,96
tak,gsk343,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",GSK343,Enhancer of zeste homolog 1 (EZH1); Enhancer of zeste homolog 2 (EZH2),1uM,96
tak,s2102,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",S2101,Lysine-Specific Demethylase 1 (LSD1) Inhibitor,10uM,96
tak,unc0628,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",UNC0628,Euchromatic histone-lysine N-methyltransferase 1 (EHMT1); Histone-lysine N-methyltransferase EHMT2 (EHMT2),1uM,96
toyo,toyo_10hr,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Toyocamycin,Antimetabolite; antineoplastic agent; bacterial metabolite; apoptosis inducer,NA,10
toyo,toyo_24hr,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Toyocamycin,Antimetabolite; antineoplastic agent; bacterial metabolite; apoptosis inducer,NA,24
toyo,toyo_2hr,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Toyocamycin,Antimetabolite; antineoplastic agent; bacterial metabolite; apoptosis inducer,NA,2
toyo,toyo_48hr,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Toyocamycin,Antimetabolite; antineoplastic agent; bacterial metabolite; apoptosis inducer,NA,48
toyo,toyo_72hr,YB5,epithelial,large intestine; colon,"Adenocarcinoma; Colorectal; Dukes' type C, grade IV",Toyocamycin,Antimetabolite; antineoplastic agent; bacterial metabolite; apoptosis inducer,NA,72